Renal Cell Carcinoma With Concurrent Loss of SMARCB1/INI-1 and Fumarate Hydratase By Immunohistochemistry: A Case Report With Review of the Literature

Résumé fourni par la source

Both SMARCB1(INI-1)-deficient and FH (fumarate hydratase)-deficient renal cell carcinoma (RCC) have a male predominance, potentially overlapping high-grade histologic features, and typically poor clinical outcomes. SMARCB1(INI-1) deficiency is the characteristic pathogenic alteration in medullary (or medullary-like) RCC, which is aggressively treated with chemotherapy, primarily platinum-based. In contrast, a distinct set of agents, such as the combination of bevacizumab and erlotinib, is the principal systemic therapy consideration for FH-deficient RCC. SMARCB1 (INI-1) is a core subunit of the SWI/SNF complex, regulating chromatin remodeling and gene transcription through epigenetics. The accumulation of fumarate, resulting from the loss of FH, can alter DNA methylation and promote a CpG island methylator phenotype (CIMP), silencing tumor suppressor genes. Rare case reports of FH-deficient RCC with concurrent loss of SMARCB1 (INI-1) have been reported, which is likely due to secondary epigenetic silencing of SMARCB1 . Herein, we report a unique RCC case with concurrent loss of SMARCB1 (INI-1) and FH expression by immunohistochemistry. Molecular studies demonstrated a SMARCB1 mutation, but no FH mutation was identified. Relatively low FH transcription was detected in the case, which raises the possibility of a pathogenic loss of SMARCB1 (INI-1), accompanied by a potential secondary, epigenetic loss of FH expression. Therefore, FH loss by IHC does not necessarily always indicate a pathogenic FH mutation. Further molecular studies are critical in determining the underlying pathogenic mutation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.